查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1992699

BREO Ellipta 药物市场：按作用机制、适应症和最终用户划分 - 2026-2032 年全球市场预测

BREO Ellipta Drugs Market by Mechanism Of Action, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年 BREO Ellipta 製药市值为 33.3 亿美元，预计到 2026 年将成长至 34.7 亿美元，复合年增长率为 4.68%，到 2032 年将达到 45.9 亿美元。

主要市场统计数据
基准年 2025 33.3亿美元
预计年份：2026年 34.7亿美元
预测年份 2032 45.9亿美元
复合年增长率 (%) 4.68%

BREO Ellipta 疗法在临床实践中的策略性引入概述了其药理学、临床效用以及在设备和药物依从性方面的差异化优势。

本执行导言概述了 BREO Ellipta 疗法在现代呼吸医学中的临床特征和策略意义。

呼吸照护路径的演变以个人化指南、数位化用药依从性技术、供应链韧性和对永续性的重视为驱动。

呼吸医学领域正在经历一场变革，其驱动力包括不断演变的指南、新技术的引入以及对以患者为中心的护理路径的重新关注。

本研究评估了 2025 年价格调整将如何影响吸入疗法的药品采购、生产在地化、价格谈判和供应弹性。

2025 年美国将实施的价格政策变更的累积影响将对吸入疗法的药品供应链、定价策略和商业性实施产生重大影响。

全面的細項分析揭示了作用机制、临床适应症的多样性以及最终用户的医疗保健环境如何决定引入途径和商业策略。

关键的细分洞察揭示了治疗机制、临床适应症和护理环境如何全面影响采用动态和商业性重点。

制定区域策略，以协调美洲、欧洲、中东、非洲和亚太地区的监管合作、为支付者提供证据以及供应链韧性。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的监管策略、报销管道和临床引入有重大影响。

竞争情报和商业情报重点在于生命週期策略、伙伴关係、数位化药物合规性和生产韧性如何决定公司的市场定位。

老牌製造商和新兴企业之间的竞争动态正在重塑产品定位、生命週期策略和伙伴关係模式。

产业领导者正在采取切实可行的策略措施，以增强其吸入疗法产品组合的市场进入，确保供应弹性，并提高患者的依从性。

这些切实可行的建议为寻求加强自身地位并加速吸入疗法持续普及的行业领导者提供了切实可行的蓝图。

本节介绍了一种混合方法研究途径，该方法结合了对临床医生的访谈、二手文献的整合以及多阶段检验，以得出可靠的研究结果。

本调查方法结合了原始质性资料、系统性的二手文献综述和严格的检验，以确保研究结果的可靠性和可操作性。

综合临床趋势、商业性需求和营运重点，总结出有助于制定吸入疗法策略决策的结论。

总之，BREO Ellipta 疗法及相关吸入性联合治疗的未来发展前景受临床进展、商业性压力和营运挑战的影响，这些因素共同决定了策略重点。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：BREO Ellipta药物市场及其作用机制

  • ICS
  • LAMA
  • LABA

第九章：BREO Ellipta药物市场：依适应症划分

  • 气喘
  • 气喘/慢性阻塞性肺病重迭综合征
  • COPD

第十章：BREO Ellipta 製药市场：依最终用户划分

  • 居家医疗
  • 医院
  • 专科诊所

第十一章 BREO Ellipta 製药市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 BREO Ellipta 製药市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 BREO Ellipta 製药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国 BREO Ellipta 製药市场

第十五章：中国 BREO Ellipta 药厂

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici SpA
  • Cipla Limited
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-81515600A1FD

The BREO Ellipta Drugs Market was valued at USD 3.33 billion in 2025 and is projected to grow to USD 3.47 billion in 2026, with a CAGR of 4.68%, reaching USD 4.59 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.33 billion
Estimated Year [2026] USD 3.47 billion
Forecast Year [2032] USD 4.59 billion
CAGR (%) 4.68%

A strategic introduction that situates BREO Ellipta therapies within clinical practice by outlining pharmacology, real-world utility, and differentiating device and adherence advantages

This executive introduction frames the clinical profile and strategic significance of BREO Ellipta therapies within contemporary respiratory medicine.

BREO Ellipta, a once-daily fixed-dose inhaled combination, integrates an inhaled corticosteroid with a long-acting beta2-agonist to deliver convenient, adherence-friendly therapy for airway inflammatory disease. Clinically, the formulation targets both maintenance therapy for asthma and the chronic management of COPD where anti-inflammatory control and bronchodilation are central to symptom reduction and exacerbation prevention. The dry powder inhaler device platform supports standardized dosing, ease of use for many patients, and compatibility with patient education programs designed to improve long-term adherence.

From a strategic lens, this product class occupies an intersection of established pharmacology and evolving therapeutic expectations. Payers and providers increasingly evaluate therapies on their real-world effectiveness, safety profile, and capacity to reduce acute care utilization. Consequently, clinical differentiators such as dosing frequency, inhaler ergonomics, and the robustness of post-marketing safety data materially shape clinician prescribing behavior and formulary positioning. Furthermore, lifecycle management opportunities-ranging from label expansions to device enhancements-remain central to sustaining therapeutic relevance amidst intensifying competition and shifting care models.

Evolving respiratory care pathways driven by guideline personalization, digital adherence technologies, supply chain resilience, and sustainability priorities

The respiratory landscape is undergoing transformative shifts driven by guideline evolution, technology adoption, and a renewed focus on patient-centric care pathways.

Guideline updates increasingly emphasize personalized approaches that match inhaled controller intensity to individual risk profiles, spurring greater interest in both dual and triple combination regimens for patients whose symptoms and exacerbation history justify escalated therapy. At the same time, technological innovation-ranging from connected inhaler sensors to telehealth-enabled adherence programs-has changed how clinicians monitor and support patients, enabling more proactive interventions and data-driven treatment optimization. These digital adjuncts also create new value propositions for therapeutics, linking pharmacologic effect with measurable improvements in daily inhaler use.

Supply chain resilience and environmental considerations are reshaping procurement and formulary choices. Manufacturers and healthcare systems are prioritizing sourcing strategies that mitigate disruption risk while also responding to institutional sustainability targets. In parallel, payers are intensifying scrutiny of long-term outcomes and total cost of care, encouraging manufacturers to demonstrate not only clinical efficacy but also economic value in real-world settings. As a result, successful products increasingly combine clinical excellence with pragmatic delivery and commercial strategies that align with evolving healthcare priorities.

Assessing how 2025 tariff changes reshape pharmaceutical sourcing, manufacturing localization, pricing negotiations, and supply resilience for inhaled therapies

The cumulative impact of tariff policy shifts implemented in the United States in 2025 has important implications for pharmaceutical supply chains, pricing strategies, and commercial execution for inhaled therapies.

Tariff adjustments that affect imported pharmaceutical ingredients, device components, and packaging materials introduce added cost volatility and compel manufacturers to reassess sourcing strategies. In response, companies are accelerating localization of key manufacturing steps, diversifying supplier portfolios, and renegotiating long-term contracts to insulate margins and maintain predictable supply. These operational changes, in turn, influence inventory planning and the cadence of product launches in affected markets. For manufacturers that rely on cross-border supply chains for active pharmaceutical ingredients or specialized inhaler components, the need for contingency planning has become a front-line commercial priority.

Beyond manufacturing, tariff-driven cost pressures can reshape pricing and reimbursement negotiations. Payers and providers may-expect greater transparency on cost drivers and may push for value-based arrangements that tie payment to patient outcomes. Consequently, commercial teams must prepare evidence dossiers that demonstrate clinical benefit and downstream cost offsets, and they must model scenarios that reflect potential supply chain cost pass-throughs. Strategic responses also include investment in manufacturing redundancy, selective onshoring of critical components, and closer collaboration with distributors and wholesalers to smooth logistical impacts on product availability.

Comprehensive segmentation analysis revealing how mechanism of action, clinical indication diversity, and end-user care settings define adoption pathways and commercial tactics

Key segmentation insights reveal how therapeutic mechanism, clinical indication, and points of care collectively shape adoption dynamics and commercial prioritization.

Based on mechanism of action, the therapeutic landscape spans inhaled corticosteroids (ICS), combined ICS/LABA regimens exemplified by fluticasone furoate vilanterol, triple-combination ICS/LAMA/LABA formulations such as fluticasone furoate umeclidinium vilanterol, as well as standalone bronchodilator classes that include LABA, LAMA with agents like umeclidinium, and dual LAMA/LABA combinations such as umeclidinium vilanterol. Within this structure, ICS/LABA combinations remain central for many patients due to their established anti-inflammatory and bronchodilatory synergy, while interest in triple therapies has risen for patients with persistent symptoms or frequent exacerbations, emphasizing the importance of comparative effectiveness data in shaping clinical decision-making.

Based on indication, the therapeutic focus spans asthma, asthma-COPD overlap presentations, and COPD as distinct clinical pathways with different therapeutic thresholds and monitoring priorities. Asthma management continues to emphasize stepwise escalation and de-escalation to balance control and safety, while COPD treatment paradigms tilt toward maximizing symptom control and minimizing exacerbation risk. Overlap phenotypes present additional complexity, requiring careful phenotyping and individualized therapy choices that often benefit from integrated care pathways and specialist input.

Based on end user, care delivery settings include homecare programs, hospitals, and specialty clinics, each with unique operational drivers. Homecare and outpatient management increasingly incorporate remote monitoring and patient education to support adherence and reduce acute visits, whereas hospitals and specialty clinics play a pivotal role in initiating advanced regimens, conducting inhaler technique training, and managing complex comorbidities. Consequently, commercial strategies that align clinician training, patient support, and distribution across these end-user settings strengthen uptake and optimize real-world therapeutic performance.

Regional strategies that align regulatory engagement, payer evidence generation, and supply chain resilience across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence regulatory strategy, reimbursement access, and clinical adoption across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

In the Americas, regulatory pathways and payer models emphasize outcome evidence and cost-effectiveness, driving manufacturers to pair clinical data with health economic analyses and patient support initiatives. The United States market in particular demands robust real-world evidence and formulary engagement strategies that address heterogenous payer requirements, while Latin American markets often reflect variability in access and procurement approaches that can favor strategic partnerships with local distributors.

Across Europe, Middle East & Africa, regulatory harmonization in some regions coexists with distinct national reimbursement frameworks that shape launch sequencing and pricing. European health systems commonly require comparative effectiveness and budget impact information for formulary inclusion, and regional sustainability initiatives can influence device choice and procurement. Meanwhile, healthcare infrastructure heterogeneity across the Middle East and Africa necessitates tailored commercial and supply approaches that accommodate variability in care delivery and procurement capacity.

In the Asia-Pacific region, rapid healthcare modernization, expanding specialist networks, and growing emphasis on chronic disease management create both opportunities and complexities. Diverse regulatory environments, varying degrees of public reimbursement, and an expanding base of patients moving into treatment paradigms drive a need for regionally adapted evidence generation and distribution strategies. Manufacturers that invest in local evidence, clinician education, and supply chain robustness are better positioned to capitalize on adoption trends across these diverse geographies.

Competitive and commercial intelligence highlighting how lifecycle strategies, partnerships, digital adherence, and manufacturing resilience define company positioning

Competitive dynamics among established manufacturers and emerging players are reshaping product positioning, lifecycle strategies, and partnership models.

Incumbent companies with established inhaled therapies are focusing on lifecycle extensions through device refinement, label updates, and real-world evidence programs that emphasize safety and long-term outcomes. At the same time, competitors are differentiating through novel combinations, alternate delivery platforms, and investments in digital adherence technologies that pair pharmacology with patient behavior management. Partnerships and alliances-ranging from co-development agreements to commercialization collaborations-have become common mechanisms to accelerate access to complementary competencies such as device engineering, digital health integration, and regional distribution networks.

Supply chain strategies and manufacturing footprint decisions also distinguish competitive approaches. Firms that proactively diversify component sourcing, adopt modular manufacturing models, and invest in regional capacity can better navigate tariff fluctuations and logistic disruptions. Commercially, companies that align pricing, patient support, and outcome measurement are more effective in payer negotiations, while those that invest in clinician education and inhaler technique training strengthen prescribing confidence and long-term adherence. Overall, competitive success increasingly rests on integrating clinical differentiation with operational excellence and value-oriented commercial models.

Practical strategic actions for industry leaders to strengthen market access, ensure supply resilience, and increase patient adherence for inhaled therapeutic portfolios

Actionable recommendations provide a pragmatic blueprint for industry leaders seeking to strengthen positioning and accelerate sustainable uptake of inhaled therapies.

First, integrate robust real-world evidence programs into launch and lifecycle strategies to demonstrate clinical and economic value across diverse care settings. Complement randomized trial data with pragmatic studies and registries that capture adherence, exacerbation rates, and healthcare utilization to support payer discussions and clinician decision-making. Second, prioritize device ergonomics and patient training as central elements of product strategy; investments in inhaler design, instructional tools, and support programs materially improve technique and adherence, which in turn drive better outcomes.

Third, diversify manufacturing and sourcing to mitigate tariff and supply chain risks by establishing regional production hubs and securing alternative suppliers for critical components. Fourth, embrace digital health adjuncts that enable remote adherence monitoring and personalized interventions, and pair these technologies with outcomes-based contracting where feasible to align value creation with reimbursement. Finally, engage early with regulatory and payer stakeholders to align evidence generation plans with approval and reimbursement requirements, ensuring smoother market access pathways and more predictable commercial rollouts. Implementing these actions in concert will strengthen resilience, enhance patient outcomes, and create defensible commercial differentiation.

Description of the mixed-methods research approach combining clinician interviews, secondary literature synthesis, and multi-stage validation to produce robust insights

The research methodology blends primary qualitative inputs, systematic secondary review, and rigorous validation to ensure credible and actionable insights.

Primary research included structured interviews with clinical specialists in respiratory medicine, pharmacy directors, hospital procurement leads, and payers to capture frontline perspectives on prescribing behavior, formulary decision drivers, and operational constraints. Secondary review encompassed peer-reviewed clinical literature, regulatory filings, device performance studies, and public policy documents to contextualize clinical and commercial trends. Evidence synthesis prioritized high-quality sources and recent publications to reflect the current therapeutic environment.

All findings underwent multi-stage validation, including cross-referencing clinician interviews with secondary data and internal expert review to ensure consistency and minimize bias. Limitations were acknowledged where data variability existed across regions or where long-term outcomes data remained emergent. The methodology emphasizes transparency in assumptions and invites stakeholders to request deeper data appendices or tailored analyses that align with specific decision-making needs.

Concluding synthesis that ties together clinical trends, commercial imperatives, and operational priorities to inform strategic decision-making for inhaled therapies

In conclusion, the landscape for BREO Ellipta therapies and related inhaled combinations is shaped by clinical evolution, commercial pressures, and operational challenges that together define strategic priorities.

Clinical practice is moving toward more personalized regimens and greater use of combined therapies where appropriate, while digital tools and adherence programs are changing how long-term control is achieved and measured. Tariff changes and supply chain considerations reinforce the need for diversified sourcing and manufacturing agility, and regional differences in regulatory and payer environments require tailored evidence generation and market access plans. Competitive advantage will accrue to organizations that integrate clinical differentiation, device and digital support, and resilient operational models that together deliver demonstrable value to patients, providers, and payers.

Looking ahead, the successful commercialization of inhaled therapies will rely as much on execution across distribution, training, and value demonstration as it does on pharmacologic efficacy. Decision-makers should therefore align clinical development, market access, and operational strategies to capture sustainable uptake and ensure that patients receive consistent, effective respiratory care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. BREO Ellipta Drugs Market, by Mechanism Of Action

  • 8.1. ICS
  • 8.2. LAMA
  • 8.3. LABA

9. BREO Ellipta Drugs Market, by Indication

  • 9.1. Asthma
  • 9.2. Asthma COPD Overlap
  • 9.3. COPD

10. BREO Ellipta Drugs Market, by End User

  • 10.1. Homecare
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. BREO Ellipta Drugs Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. BREO Ellipta Drugs Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. BREO Ellipta Drugs Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States BREO Ellipta Drugs Market

15. China BREO Ellipta Drugs Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. AstraZeneca plc
  • 16.6. Boehringer Ingelheim International GmbH
  • 16.7. CHIESI Farmaceutici S.p.A.
  • 16.8. Cipla Limited
  • 16.9. GlaxoSmithKline plc
  • 16.10. Hikma Pharmaceuticals PLC
  • 16.11. Lupin Pharmaceuticals, Inc.
  • 16.12. Merck & Co., Inc.
  • 16.13. Novartis AG
  • 16.14. Orion Corporation
  • 16.15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREO ELLIPTA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BREO ELLIPTA DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA BREO ELLIPTA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LAMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LABA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LABA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LABA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA COPD OVERLAP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA COPD OVERLAP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA COPD OVERLAP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 34. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 35. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 36. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 39. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. NORTH AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 43. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 44. LATIN AMERICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 46. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 47. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 48. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 55. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 56. MIDDLE EAST BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 59. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 68. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. ASEAN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 72. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. GCC BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPEAN UNION BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 80. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. BRICS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 84. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. G7 BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 88. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. NATO BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 93. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. CHINA BREO ELLIPTA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 96. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 97. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)